ADMA Biologics, Inc.(ADMA)Earnings, Financials & Key RatiosADMA Biologics, Inc. (ADMA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's forward P/E of 10.57 and consistent improvement in retained earnings suggest a compelling valuation for a firm that has successfully scaled its operating income to $58.3 million.
ADMA Biologics, Inc. (ADMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ADMA Biologics, Inc. (ADMA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.19vs $0.19-1.7% | $114Mvs $140M-18.2% |
| Q1 2026 | Feb 25, 2026 | $0.20vs $0.18+8.1% | $139Mvs $140M-0.3% |
| Q4 2025 | Nov 5, 2025 | $0.16vs $0.16+0.0% | $134Mvs $140M-4.0% |
| Q3 2025 | Aug 6, 2025 | $0.15vs $0.14+7.1% | $122Mvs $130M-6.4% |
Recent stock market news and headlines for ADMA Biologics, Inc. (ADMA)
Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.
Key metrics vs top competitors for ADMA Biologics, Inc. (ADMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.21 | $2.13B | 15.35 | 19.63% | 28.8% | 35.56% | — | |
| $7.21 | $6.1B | 11.07 | 0.2% | 5.58% | 5.43% | — | |
| $292.50 | $7.9B | 10.50 | 0.65% | 6.52% | 2.4% | — | |
| $0.08 | $360.49K | -0.04 | -35.82% | -709.4% | -453.74% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $353.87 | $14.47B | 20.67 | 0.33% | 14.57% | 34.48% | — |
ADMA Biologics, Inc. (ADMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADMA Biologics, Inc. (ADMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
May 4, 2026·SEC
Mar 27, 2026·SEC
Get notified when ADMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADMA Biologics, Inc. (ADMA) stock FAQ — growth, dividends, profitability & financials explained
ADMA Biologics, Inc. (ADMA) reported $509.9M in revenue for fiscal year 2025.
ADMA Biologics, Inc. (ADMA) grew revenue by 19.6% over the past year. This is strong growth.
Yes, ADMA Biologics, Inc. (ADMA) is profitable, generating $165.4M in net income for fiscal year 2025 (28.8% net margin).
ADMA Biologics, Inc. (ADMA) has a return on equity (ROE) of 35.6%. This is excellent, indicating efficient use of shareholder capital.
ADMA Biologics, Inc. (ADMA) generated $107.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
